Pacira BioSciences Inc [PCRX] stock is trading at $20.18, down -5.08%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PCRX shares have lost -0.86% over the last week, with a monthly amount drifted -4.18%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Pacira BioSciences Inc [NASDAQ: PCRX] stock has seen the most recent analyst activity on July 03, 2024, when Barclays downgraded its rating to a Equal Weight and also revised its price target to $25 from $38. On December 20, 2023, Raymond James initiated with a Outperform rating and assigned a price target of $42 on the stock. TD Cowen upgraded its rating to a Outperform but stick to its price target of $50 on August 03, 2023.
Pacira BioSciences Inc [PCRX] stock has fluctuated between $19.34 and $40.16 over the past year. Currently, Wall Street analysts expect the stock to reach $50 within the next 12 months. Pacira BioSciences Inc [NASDAQ: PCRX] shares were valued at $20.18 at the most recent close of the market. An investor can expect a potential return of 147.77% based on the average PCRX price forecast.
Analyzing the PCRX fundamentals
Pacira BioSciences Inc [NASDAQ:PCRX] reported sales of 690.31M for the trailing twelve months, which represents a growth of 5.05%. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at 0.14%, Pretax Profit Margin comes in at 0.15%, and Net Profit Margin reading is 0.09%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.07 and Total Capital is 0.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.68.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.77 points at the first support level, and at 19.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 20.56, and for the 2nd resistance point, it is at 20.95.
Ratios To Look Out For
For context, Pacira BioSciences Inc’s Current Ratio is 6.82. As well, the Quick Ratio is 5.70, while the Cash Ratio is 2.67. Considering the valuation of this stock, the price to sales ratio is 1.35, the price to book ratio is 1.06 and price to earnings (TTM) ratio is 15.69.
Transactions by insiders
Recent insider trading involved SLONIN JONATHAN, Officer, that happened on Aug 02 ’24 when 945.0 shares were purchased. Chief Medical Officer, SLONIN JONATHAN completed a deal on Aug 02 ’24 to sell 945.0 shares. Meanwhile, Chief Medical Officer SLONIN JONATHAN sold 2836.0 shares on Jul 02 ’24.
